Raymond James analyst Jayson Bedford downgraded AngioDynamics to Outperform from Strong Buy with a price target of $13, down from $14. Uncertainties around potential liabilities are largely factored into the stock price, but this overhang should continue to weigh on sentiment until a resolution appears, the analyst tells investors in a research note. The firm believes there is more value in the business and hopes that the board will pursue more "creative" paths for value creation.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ANGO:
- Needham med tech analysts to hold an analyst/industry conference call
- AngioDynamics price target lowered to $18 from $26 at Canaccord
- AngioDynamics cuts FY23 adjusted EPS view to (6c)-(1c) from 1c-6c
- AngioDynamics reports Q3 EPS (3c), consensus (1c)
- Angiodynamics, Inc. (ANGO) Q3 Earnings Cheat Sheet